Additionally, previous studies combining PSMA-targeted alpha therapies, either thorium-227-HOPO-pelgifatamab (227Th-pelgi) or actium-225-macropa-pelgifatamab (225Ac-pelgi), and darolutamide have shown enhanced antitumor efficacy in preclinical prostate cancer models, which is consistent with the darolutamide-induced suppression of DDR signaling [7,23]. This evidence concerns the gene FOLH1 and prostate carcinoma.